<?xml version="1.0" encoding="UTF-8"?>
<p id="p0075">Anti-viral therapy which are currently used for the treatment of influenza viruses, have the limitations on vaccine design, efficacy and delay in vaccine production because of the evolution of drug-resistant viral mutants attributed to the mutation or reassortment potential of this virus [
 <xref rid="bib59" ref-type="bibr">59</xref>, 
 <xref rid="bib60" ref-type="bibr">60</xref>]. Studies are taking place to isolate new antiviral agents from natural compounds.
</p>
